Gene set enrichment analysis showed elevated expression of pathways relating to immune cells (including CD8 T cells, NK cells, and macrophages), IFNγ, and an antigen presenting gene signature in PD-L1 positive, HA − tumors in both the tislelizumab-treated GEA cohort and pembrolizumab-treated GC cohort (Fig. 4c, d). The gene discussed is IFNG; the disease is gastric cancer.